Get the Stockscreener App
573.91
1.12%
-6.50
Regeneron Pharmaceuticals Inc stock is traded at $573.91, with a volume of 767.81K.
It is down -1.12% in the last 24 hours and up +5.79% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$580.41
Open:
$582.09
24h Volume:
767.81K
Relative Volume:
0.66
Market Cap:
$59.78B
Revenue:
$14.21B
Net Income/Loss:
$4.46B
P/E Ratio:
14.46
EPS:
39.68
Net Cash Flow:
$3.56B
1W Performance:
+5.12%
1M Performance:
+5.79%
6M Performance:
-15.60%
1Y Performance:
-51.34%
1-Day Range:
$573.81
$585.00
1-Week Range:
$547.09
$585.00
52-Week Range:
$476.49
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
573.91 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.88 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.87 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.32 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
319.32 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Sienna Gestion Has $5.65 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Stock Slumps as Trading Volume Plunges 31% to 440M Ranking 207th in U.S. Activity - AInvest
Tocqueville Asset Management L.P. Takes $54.50 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Leo Keeps On Profitable Path With Solid H1 Sales Growth - insights.citeline.com
Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™ - GlobeNewswire Inc.
Dimensional Fund Advisors LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Prudential PLC Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
National Pension Service Purchases 20,596 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by E Fund Management Co. Ltd. - MarketBeat
Independent Advisor Alliance Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Gulf International Bank UK Ltd Reduces Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Public Sector Pension Investment Board - MarketBeat
1,038 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by S Bank Fund Management Ltd - MarketBeat
Tokio Marine Asset Management Co. Ltd. Has $9.55 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Russell Investments Group Ltd. Has $93.08 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Resona Asset Management Co. Ltd. Acquires 1,225 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
How volatile is Regeneron Pharmaceuticals Inc. stockTrade Volume Report & Technical Confirmation Alerts - thegnnews.com
Aberdeen Group plc Purchases 56,746 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fox Run Management L.L.C. Purchases New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Strong-Buy at Redburn Atlantic - MarketBeat
American Century Companies Inc. Grows Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Element Capital Management LLC Acquires Shares of 4,265 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Rothschild & Co Redburn - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Invesco Ltd. - MarketBeat
Cary Street Partners Financial LLC Sells 959 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game Changer - TipRanks
Regeneron’s Phase 3 Study on Garetosmab: A Potential Game-Changer for FOP Treatment - TipRanks
Can Eylea HD and Dupixent Profits Revive Regeneron Stock? - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
Mizuho Securities USA LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
How Will Regeneron’s (REGN) Solid Earnings and R&D Progress Shape Its Risk-Reward Balance? - simplywall.st
Michael Burry's Scion starts new position in UnitedHealth, lululemon and Regeneron among top Q2 moves - MSN
Nuveen LLC Purchases Shares of 542,018 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Aigen Investment Management LP Has $1.69 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Entropy Technologies LP - MarketBeat
Townsquare Capital LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Ex-Dividend Reminder: ONE Gas, iRadimed and Regeneron Pharmaceuticals - Nasdaq
Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN - TipRanks
Regeneron stock price target maintained at $780 by TD Cowen on pipeline strength - Investing.com Canada
Regeneron’s Promising Study on Platinum-Resistant Ovarian Cancer - TipRanks
Rothschild bullish on Regeneron as pipeline strength outweighs Eylea decline - Investing.com Canada
Rothschild Redburn initiates Regeneron stock with Buy rating, $890 target By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by National Bank of Canada FI - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Decreased by Swiss National Bank - MarketBeat
Fund Update: DODGE & COX added 1,502,198 shares of REGENERON PHARMACEUTICALS (REGN) to their portfolio - Quiver Quantitative
Citizens Financial Group Inc. RI Sells 465 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform - MSN
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):